Hello from Greycoat Research,

This is Claire J.E Yun, Founder of Greycoat Research.

A few days ago, TT had her routine bloodwork done at the veterinary clinic for the first time in about a year.

TT is my grey-coated cat. I have been caring for her chronic kidney disease since 2019, and she is also the reason Greycoat Research began.

TT was diagnosed with chronic kidney disease in 2019.
In her latest bloodwork, her results showed Creatinine 2.1 and BUN 18.

Since her Stage 2 CKD diagnosis,
TT has remained stable through ongoing care for 8 years.

I am deeply grateful that TT’s kidney condition has remained stable over such a long period of time.

I also hope more cat parents caring for cats with kidney disease
can find a routine that works for their cat
and help their cats maintain a more stable daily life, just as TT has.

Greycoat Research Began With One Cat

Greycoat Research began with TT’s kidney care journey.

At first, it was a deeply personal search for a better way to care for her.

But that search gradually became something more:
daily records, repeated bloodwork, diet management, nutritional routines,
and research into better possibilities for cats with kidney disease.

Today, Greycoat Research has grown into a brand supporting the care of
more than 15,000 cats with chronic kidney disease.

And now, guided by Dr. Toru Miyazaki’s AIM research,
we work with veterinarians, veterinary nutrition specialists, and pharmacists
to study more specialized approaches to CKD care for cats.

Why We Created Our Story

We recently updated the Our Story section on our website.

This page is not simply a brand introduction or a product explanation.

We created it to show where Greycoat Research began,
why we became focused on cat kidney care,
and what direction we are moving toward.

[View Our Story]

What Comes Next for Greycoat Research

Greycoat Research’s next step has already begun.

We are preparing to introduce a genetic test designed to identify whether a cat carries a genetic variant in AIM Exon 3.

We believe cats with AIM-related genetic characteristics may need a more structured and personalized approach
than general kidney care alone.

Greycoat Research is also studying long-term care data from cats with Stage 2 and Stage 3 CKD
to explore approaches beyond the conventional, one-size-fits-all model.

In particular, we have repeatedly observed some Stage 3 CKD cats
returning to a more stable pattern in their kidney values
and maintaining that stability over time.

We do not see these records as simple caregiver testimonials or isolated cases.

Based on this data, Greycoat Research is studying the possibility of
stopping the progression of feline kidney disease.

This year, together with researchers and clinical experts on the Greycoat Research team,
we are preparing a paper on the long-term stability of feline kidney disease
and a new care approach aimed at stopping disease progression.

Our goal is clear.

We do not want to look at feline kidney disease only as a condition that slowly gets worse.

Through more precise gene-based data and structured care routines,
we aim to develop a care model that can change the course of kidney disease progression itself.

We will continue working so that more cats with CKD
can find the routine that fits them
and live a longer, more stable daily life.

Warmly,
Claire J.E Yun
Founder, Greycoat Research